Skip to
  1. Homepage
  2. Rare diseases
  3. Search
Simple search

Simple search

*
(*) mandatory field





 

Other search option(s)

X-linked lymphoproliferative disease

Orpha number ORPHA2442
Synonym(s) Duncan disease
Purtilo syndrome
XLP
Prevalence <1 / 1 000 000
Inheritance X-linked recessive
Age of onset Childhood
ICD-10
  • D82.3
ICD-O -
OMIM
UMLS
  • C0549463
MeSH
  • D008232
MedDRA
  • 10068348

Summary

X-linked lymphoproliferative disease is a hereditary immunodeficiency characterized, in the majority of cases, by an inadequate immune response to infection with the Epstein-Barr virus (EBV).

Prevalence in males is estimated at 1/1, 000,000.

Infection with the Epstein-Barr virus can result in one or several of the following manifestations: fulminant infectious mononucleosis, macrophage-activation syndrome or hemophagocytic lymphohistiocytosis (HLH) (see these terms), and/or progressive hypogammaglobulinemia and/or lymphomas. Hemophagocytic lymphohistiocytosis is a potentially fatal complication, caused by activation and excessive proliferation of T cells and macrophages, which manifests as fever, hepatosplenomegaly and lymphadenopathy. Coagulopathy and central nervous system dysfunction can follow as well as multiple organ failure syndrome. In rare cases, aplastic anemia and lymphocytic vasculitis are observed. In some cases the same phenotype is observed in the absence of infection with Epstein-Barr virus.

In 60% of cases the gene responsible codes for the protein SAP (signaling lymphocyte activation molecule (SLAM)-associated protein), which regulates T lymphocyte activation. In three families without mutations of the SH2D1A gene, mutations of the gene which codes for the protein XIAP (X-linked inhibitor of apoptosis), also called BIRC4, have been identified. The failure to express XIAP is associated with increased apoptosis of lymphocytes triggered by diverse stimuli. Patients with SAP and XIAP deficiency have few natural killer T lymphocytes (NKT cells), which suggests that NKT cells play a key role in the immune response to EBV.

Definitive diagnosis is based on genetic analysis.

Differential diagnoses include other hereditary forms of HLH (familial lymphohistiocytosis; see this term) and HLH acquired through infection with EBV.

Antenatal diagnosis with mutation analysis can be done when the mutation has been identified in the family.

Transmission is X-linked recessive.

The only cure for X-linked lymphoproliferative disease (SAP or XIAP deficiency) is by a hematopoietic stem cell allotransplantation. Treatment of HLH requires the use of corticosteroids, chemotherapy by VP16 (according to the protocol HLH-2004) or by antithymocyte globulin. The anti-CD20 antibody (Rituximab) can be used to reduce the EBV viral load and indirectly reduce T lymphocyte activation.

Prognosis depends on the occurrence of complications, such as lymphomas and hemophagocytic lymphohistiocytosis.

Expert reviewer(s)

  • Pr Alain FISCHER

(*) Required fields.

Attention: Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. For all other comments, please send your remarks via contact us. Only comments written in English can be processed.


Captcha image

Detailed information

Summary information
Review article
  • IT (2008)
  • EN (2008)
Clinical genetics review
  • EN (2013)
Get Acrobat Reader
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.